Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394991 | 1.00 | AKR1C3 (0.43) | AKR1C3CA1CA2ERN1APEX1 | |
| SCHEMBL7822855 | 0.84 | GABRA1 (0.56) | AKR1C3APEX1TDP1ALDH1A1TSHR | |
| SCHEMBL7822858 | 0.84 | GABRA1 (0.56) | AKR1C3APEX1TDP1ALDH1A1TSHR | |
| SCHEMBL7880143 | 0.81 | ABL1 (0.42) | AKR1C3APEX1TDP1ALDH1A1CYP3A4 | |
| SCHEMBL7880140 | 0.81 | ABL1 (0.42) | AKR1C3APEX1TDP1ALDH1A1CYP3A4 | |
| SCHEMBL24176985 | 0.79 | AKR1C3 (0.43) | AKR1C3CA1CA2APEX1ALDH1A1 | |
| SCHEMBL1786006 | 0.79 | AKR1C3 (0.43) | AKR1C3APEX1 | |
| SCHEMBL1786005 | 0.79 | AKR1C3 (0.43) | AKR1C3APEX1 | |
| SCHEMBL9358828 | 0.77 | TRIM24 (0.60) | ERN1APEX1ALDH1A1CYP3A4 | |
| SCHEMBL1745376 | 0.76 | TTR (0.53) | AKR1C3APEX1HSD17B10GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-8022248-B2 | 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid | ASTRAZENECA AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | AKR1C3 257/4885CA1 3310/4885CA2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.